GlassScriptPhysician profile
Tu H Cao
NPI 1063607232
$4,045.66
in general payments reported to CMS, 2019-2025
21 companies · $804 in 2025
The $804 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $18.72 · 2021: $937 · 2022: $983 · 2023: $483 · 2024: $632 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,413.58 | 2021-2023 | Cardiomems |
| Novo Nordisk INC | $577.57 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $365.22 | 2023-2025 | Otezla, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $248.27 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $219.06 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Philips North America LLC | $195.97 | 2019-2021 | |
| Pfizer INC. | $142.67 | 2023-2025 | |
| Medtronic, INC. | $130.92 | 2021 | |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Corium, LLC | $94.50 | 2023 | Azstarys |
| Exact Sciences Corporation | $92.79 | 2024-2025 | Cologuard Collection Kit |
| Abiomed | $80.61 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $60.79 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.92 | 2024-2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.89 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $25.55 | 2025 | Capvaxive, Enflonsia |
| Collegium Pharmaceutical, INC. | $24.36 | 2025 | Belbuca |
| Astellas Pharma US INC | $23.49 | 2024 | Veozah |
| Medtronic Vascular, INC. | $18.72 | 2020 | |
| Irhythm Technologies, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tu Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.